title: New trends in molecular and cellular biomarker discovery for colorectal cancer.
abstract: Colorectal cancer (CRC) is the third leading cause of cancer death worldwide, which is consequence of multistep tumorigenesis of several genetic and epigenetic events. Since CRC is mostly asymptomatic until it progresses to advanced stages, the early detection using effective screening approaches, selection of appropriate therapeutic strategies and efficient follow-up programs are essential to reduce CRC mortalities. Biomarker discovery for CRC based on the personalized genotype and clinical information could facilitate the classification of patients with certain types and stages of cancer to tailor preventive and therapeutic approaches. These cancer-related biomarkers should be highly sensitive and specific in a wide range of specimen(s) (including tumor tissues, patients' fluids or stool). Reliable biomarkers which enable the early detection of CRC, can improve early diagnosis, prognosis, treatment response prediction, and recurrence risk. Advances in our understanding of the natural history of CRC have led to the development of different CRC associated molecular and cellular biomarkers. This review highlights the new trends and approaches in CRC biomarker discovery, which could be potentially used for early diagnosis, development of new therapeutic approaches and follow-up of patients.
authors.affiliation: Parisa Aghagolzadeh, Ramin Radpour, Department of Clinical Research, University Hospital of Bern, 3010 Bern, Switzerland.
authors.forename: Parisa
authors.initials: P
authors.lastname: Aghagolzadeh
authors.affiliation: Parisa Aghagolzadeh, Ramin Radpour, Department of Clinical Research, University Hospital of Bern, 3010 Bern, Switzerland.
authors.forename: Ramin
authors.initials: R
authors.lastname: Radpour
mesh_terms: D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D043171:Chromosomal Instability / Q000235:genetics; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood; D005243:Feces / Q000737:chemistry; D006801:Humans; D007249:Inflammation; D035683:MicroRNAs / Q000097:blood / Q000378:metabolism; D009154:Mutation; D009360:Neoplastic Cells, Circulating; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D016615:Telomere / Q000378:metabolism; D059467:Transcriptome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D051176:beta Catenin / Q000235:genetics
chemical_list: C555337:APC protein, human; D025601:Adenomatous Polyposis Coli Protein; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; C117307:KRAS protein, human; D035683:MicroRNAs; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051176:beta Catenin; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras)
keywords: Biomarkers; Cancer diagnosis; Cancer therapy; Colorectal cancer; Predictive marker; Prognostic marker